Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.64 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.36 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.36 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29817411 | 1.00 | ESR1 (0.64) | ESR1ESR2CRHR1MEN1KMT2A | |
| SCHEMBL5501902 | 0.93 | ESR1 (0.78) | ESR1ESR2CRHR1MEN1KMT2A | |
| SCHEMBL4030022 | 0.90 | ESR1 (0.75) | ESR1ESR2CRHR1PDE4BPDE4D | |
| SCHEMBL4029130 | 0.87 | ESR1 (0.46) | ESR1ESR2CRHR1MEN1KMT2A | |
| SCHEMBL4027158 | 0.85 | ESR1 (0.45) | ESR1ESR2CRHR1MEN1KMT2A | |
| SCHEMBL4034557 | 0.85 | ESR1 (0.44) | ESR1ESR2CRHR1MEN1KMT2A | |
| SCHEMBL4031240 | 0.84 | ESR1 (0.58) | ESR1ESR2TSHRALDH1A1MAPT | |
| SCHEMBL4032697 | 0.83 | ESR1 (0.43) | ESR1ESR2CRHR1MEN1KMT2A | |
| SCHEMBL4031100 | 0.83 | ESR1 (0.43) | ESR1ESR2CRHR1MEN1KMT2A | |
| SCHEMBL1407773 | 0.83 | ESR1 (0.45) | ESR1ESR2CRHR1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7555415-B2 | Methods for the design of estrogen receptor ligands | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7304073-B2 | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1856151-A2 | ESTROGEN RECEPTOR STRUCTURE | Wyeth (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2006078733-A2 | ESTROGEN RECEPTOR STRUCTURE | WYETH (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160836-A1 | Estrogen receptor structure | WYETH | 2006-07-20 | — | — | US | disclosed |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060111574-A1 | Preparation and purification of 4-(indazol-3-yl) phenols | WYETH (US) | 2006-05-25 | — | — | US | disclosed |
| US-20050119276-A1 | Methods of treating inflammatory bowel disease using NF-kB inhibitors | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050119324-A1 | Methods of treating atherosclerosis using NF-kB inhibitors | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050113405-A1 | Methods of treating rheumatoid arthritis using NF-kB inhibitors | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005039583-A1 | METHOD OF TREATING RHEUMATOID ARTHRITIS USING NF-kB INHIBITORS | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039581-A1 | USE OF ESTROGEN RECEPTOR LIGANDS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885ESR2 621/4885CRHR1 2217/4885 |
| US-20050113405-A1 | Methods of treating rheumatoid arthritis using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | ESR1 14/4885ESR2 10/4885CRHR1 810/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | ESR1 2487/4885ESR2 605/4885CRHR1 2181/4885 |
| US-20050119324-A1 | Methods of treating atherosclerosis using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | ESR1 14/4885ESR2 8/4885CRHR1 1558/4885 |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | IKBKB, NFKBIA, IKBKG | ESR1 19/4885ESR2 11/4885CRHR1 1375/4885 |
| US-20050119276-A1 | Methods of treating inflammatory bowel disease using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | ESR1 14/4885ESR2 9/4885CRHR1 648/4885 |
| US-20060111574-A1 | Preparation and purification of 4-(indazol-3-yl) phenols | H1-10, KCNH3, H1-0 | ESR1 3185/4885ESR2 4011/4885CRHR1 4220/4885 |
| US-20060160836-A1 | Estrogen receptor structure | ESR2, ESR1, ESRRG | ESR1 2/4885ESR2 1/4885CRHR1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.